"PH94B Could Become First Rapid-Onset Treatment for SAD" - William Blair Reiterates Outperform Rating on VistaGen Therapeutics (VTGN)
Tweet Send to a Friend
William Blair analyst Tim Lugo reiterated an Outperform rating on VistaGen Therapeutics (NASDAQ: VTGN). The analyst comments: "We rate shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
